How many grafts for a successful transplant? 9/8/2026
A 26-year-old male has stabilized hair loss after 18 months using Hims 2 in 1 spray and is considering a hair transplant, needing about 5,000–6,000 grafts for density and a forward hairline. Oral medication is suggested for better results.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity To go from photo 1 to photo 2 & 3 is kinda mind blowing to me. My barber today told me my hair looks thicker, it made my day.
A user shared progress pictures showing thicker hair after 8 months of using Fin/Min spray from HIMS. The conversation includes skepticism and humor from other users.
community Update on taking hims spray. I cut my dose to EOD, 2-3 sprays; instead of 4 sprays everyday. Trying to mitigate any leakage of fin into bloodstream.
A user shared progress pictures and discussed their hair loss treatment, including using Hims spray with finasteride, oral finasteride, castor oil, and derma rolling. They reduced their Hims spray dose to every other day to minimize finasteride absorption into the bloodstream.
community Anyone try the 4 in 1 Spray w/ Minoxidil 5%, Caffeine .2%, Melatonin .1%, Tretinoin .01% (81 G)?
The conversation is about a user considering switching to a 4 in 1 spray containing Minoxidil, Caffeine, Melatonin, and Tretinoin for hair loss after using a finasteride and minoxidil spray. The user recently switched to oral finasteride and is contemplating whether to continue using the remaining finasteride and minoxidil spray.
community Got some results but hoping for more.
The user is using Hims Spray daily, ketoconazole shampoo 1-2 times a week, and dermastamping weekly or biweekly for hair loss treatment. They have seen some progress but are hoping for more results over time.
community Rx hair spray that contains 2% keto AND Keto shampoo? Too much?
Using a daily hair spray with 0.3% finasteride, 7% minoxidil, 2% ketoconazole, and biotin, along with a 1% ketoconazole shampoo once or twice a week, may be excessive according to the product's recommendations. The user is unsure about this regimen for treating androgenetic alopecia (AGA).
Related Research
6 / 6 results
research Index
This index of Harper's Textbook of Pediatric Dermatology, Fourth Edition, provides no clinical results or new findings.
research Continued treatment with baricitinib results in meaningful scalp responses among scalp non‐responder patients with eyebrow/eyelash regrowth in the first year
This study found that nearly 40% of patients with severe alopecia areata who showed eyebrow or eyelash regrowth on baricitinib 4 mg achieved significant scalp hair regrowth by the second year of treatment.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.
research Efficacité à long terme du baricitinib dans le traitement de la pelade : résultats à la semaine 104 des études BRAVE-AA1 et BRAVE-AA2
In this study, researchers found that among adults with severe alopecia, continued treatment with baricitinib for 104 weeks maintained hair regrowth effectively in those who responded at 52 weeks, with improved outcomes noted in some initially non-responders receiving 4 mg.
research Concordance between clinician-reported and patient-reported outcomes of eyebrow and eyelash hair loss in patients with severe alopecia areata: Results from BRAVE-AA1 and BRAVE-AA2 studies
This study evaluated the agreement between clinician and patient assessments of eyebrow and eyelash hair loss severity in adults with severe alopecia areata, using data from two phase 3 studies over 52 weeks.
research Factors influencing alopecia areata treatment decisions: A qualitative assessment
This study found that patients with alopecia areata face challenges like medical uncertainty and lack of information, highlighting the need for reliable and accessible treatment information that aligns with their preferences.